trans-decahydroisoquinoline | 2744-09-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: trans-decahydroisoquinoline
• 英文别名: trans-perhydroisoquinoline；(4aR,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline
• CAS: 2744-09-4
• 化学式: C₉H₁₇N
• 分子量: 139.241
• InChiKey: NENLYAQPNATJSU-RKDXNWHRSA-N

物化性质

• 沸点：
  87 °C / 12mmHg
• 密度：
  0,93 g/cm3
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933499090
• 储存条件：
  存储于阴凉干燥处即可。

SDS

---

Section I.Chemical Product and Company Identification
Chemical Name trans-Decahydroisoquinoline
Portland OR
trans-Perhydroisoquinoline
Synonym
C9H17N
Chemical Formula
CAS Number 2744-09-4

---

Section II. Composition and Information on Ingredients
Chemical Name CAS Number Percent (%) TLV/PEL Toxicology Data
trans-Decahydroisoquinoline 2744-09-4 Min. 97.0 Not available. Not available.
(GC)

---

Section III. Hazards Identification
Acute Health Effects Harmful if ingested or inhaled. Minimize exposure to this material. Severe overexposure can result in injury or death.
Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the
eye is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening,
or, occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Chronic Health Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

---

Section IV. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Get medical attention.
Skin Contact In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
Inhalation If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Ingestion
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the
toxic material was ingested; the absence of such signs, however, is not conclusive.

---

Section V. Fire and Explosion Data
Not available.
Flammability May be combustible at high temperature. Auto-Ignition
Flash Points Flammable Limits Not available.
105°C (221°F).
Combustion Products These products are toxic carbon oxides (CO, CO2), nitrogen oxides (NOx).
Fire Hazards
Not available.
Explosion Hazards Risks of explosion of the product in presence of mechanical impact: Not available.
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
SMALL FIRE: Use DRY chemical powder.
LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
and Instructions
Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
trans-Decahydroisoquinoline

---

Section VI. Accidental Release Measures
Spill Cleanup Harmful material. Irritating material.
Absorb with an inert material and put the spilled material in an appropriate waste disposal. Finish cleaning the spill by
Instructions
rinsing any contaminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for
assistance on disposal.

---

Section VII. Handling and Storage
Handling and Storage HARMFUL. IRRITANT. Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the container
and store in a dry, cool place. Avoid excessive heat and light. Do not breathe gas/fumes/ vapor/spray.
Information
Always store away from incompatible compounds such as oxidizing agents.

---

Section VIII. Exposure Controls/Personal Protection
Engineering Controls Provide exhaust ventilation or other engineering controls to keep the airborne concentrations of vapors below their
respective threshold limit value. Ensure that eyewash station and safety shower is proximal to the work-station location.
Personal Protection Splash goggles. Lab coat. Vapor respirator. Boots. Gloves. Suggested protective clothing might not be sufficient;
consult a specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Exposure Limits Not available.

---

Section IX. Physical and Chemical Properties
Solubility
Physical state @ 20°C Liquid. (Light Yellow Clear.) Not available.
0.93 (water=1)
Specific Gravity
Molecular Weight 139.24 Partition Coefficient Not available.
Boiling Point 87°C (188.6°F) @ 12 mmHg Vapor Pressure Not available.
Melting Point Not available. Vapor Density Not available.
1.485-1.487 Volatility Not available.
Refractive Index
Critical Temperature Not available. Odor Not available.
Viscosity Not available. Taste Not available.

---

Section X. Stability and Reactivity Data
Stability

---

This material is stable if stored under proper conditions. (See Section VII for instructions)
Conditions of Instability Avoid excessive heat and light.
Incompatibilities
Reactive with strong oxidizing agents.

---

Section XI. Toxicological Information
Not available.
RTECS Number
Eye Contact. Ingestion. Inhalation.
Routes of Exposure
Toxicity Data Not available.
Chronic Toxic Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Acute Toxic Effects Harmful if ingested or inhaled. Minimize exposure to this material. Severe overexposure can result in injury or death.
Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the
eye is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening,
or, occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Continued on Next Page
trans-Decahydroisoquinoline

---

Section XII. Ecological Information
Ecotoxicity Not available.
Not available.
Environmental Fate

---

Section XIII. Disposal Considerations
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
Waste Disposal
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

---

Section XIV. Transport Information
DOT Classification Not a DOT controlled material (United States).
Not applicable.
PIN Number
Proper Shipping Name
Not applicable.
Packing Group (PG) Not applicable.
DOT Pictograms

---

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS Classification Not available.
(Canada)
EINECS Number (EEC) Not available.
EEC Risk Statements R20/21/22- Harmful by inhalation, in contact with skin and if swallowed.
R36/37/38- Irritating to eyes, respiratory system and skin.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  trans-decahydroisoquinoline 在 正丁基锂 、 dicobalt octacarbonyl 、 十二羰基三钌 、 一氧化碳 作用下， 以 苯 为溶剂， 25.0~220.0 ℃ 、5.47 MPa 条件下， 反应 76.0h， 生成 (4aS,8aR)-2-(3,3-Dimethyl-butyl)-octahydro-isoquinolin-1-one
  参考文献：
  名称：

  通过金属催化的扩环-羰基化反应区域选择性合成哌啶酮。显着的钴和/或钌羰基催化的重排和环化反应

  摘要：

  由羰基钴催化的吡咯烷的羰基化导致哌啶酮的形成。在大多数情况下，该反应是区域特异性的，当羰基钌作为第二催化剂存在时，产物的产率会增加。双催化体系 [Co 2 (CO) 8 /Ru 3 (CO) 12 ] 可用于杂环氮酮 ((CH 2 ) n NCH 2 COR, n=4-7] 在 72- 93% 的产率。2,6-二甲基哌啶基酮的一种不寻常的金属催化环化反应以 86-94% 的产率提供了 5,6,7,8-四氢茚茚

  DOI：

  10.1021/ja00044a010
• 作为产物：
  描述：

  异喹啉 在 正丙胺 、 lithium 作用下， 生成 trans-decahydroisoquinoline
  参考文献：
  名称：

  The Lithium-Amine Reduction of Derivatives of Isoquinoline and Quinoline. A Route to trans-Decahydroisoquinoline

  摘要：

  DOI：

  10.1021/ja01556a028

文献信息

• Ni⁰-catalyzed Direct Amination of Anisoles Involving the Cleavage of Carbon–Oxygen Bonds
  作者：Mamoru Tobisu、Toshiaki Shimasaki、Naoto Chatani

  DOI：10.1246/cl.2009.710

  日期：2009.7.5

  Ni 0 -catalyzed cross-coupling of aryl methyl ethers with amines is described. The use of an N-heterocyclic carbene as a ligand and NaOt-Bu as a base promotes the amination of anisole derivatives via the cleavage of normally unreactive aryl carbon-oxygen bonds.

  描述了 Ni 0 催化的芳基甲基醚与胺的交叉偶联。使用 N-杂环卡宾作为配体和 NaOt-Bu 作为碱促进苯甲醚衍生物通过通常不活泼的芳基碳-氧键的断裂进行胺化。
• Practical and regioselective amination of arenes using alkyl amines
  作者：Alessandro Ruffoni、Fabio Juliá、Thomas D. Svejstrup、Alastair J. McMillan、James J. Douglas、Daniele Leonori

  DOI：10.1038/s41557-019-0254-5

  日期：2019.5

  these molecules are assembled through the stepwise introduction of a reactivity handle in place of an aromatic C-H bond (that is, a nitro group, halogen or boronic acid) and a subsequent functionalization or cross-coupling. Here we show that aromatic amines can be constructed by direct reaction of arenes and alkyl amines using photocatalysis, without the need for pre-functionalization. The process

  用于制备芳香胺的碳-氮键的形成是全球范围内为生产高价值材料而进行的前五项反应之一，从原料化学品到药物和聚合物不等。由于这种普遍性和多样性，其制备方法影响了学术界和工业界的整个化学合成过程。通常，这些分子是通过逐步引入反应性手柄代替芳香族CH键（即硝基，卤素或硼酸）和随后的功能化或交叉偶联而组装而成的。在这里，我们表明，芳烃胺可以使用光催化作用，通过芳烃和烷基胺的直接反应来构建，而无需进行预功能化。该过程可以轻松准备高级构建基块，容忍的功能范围很广，并且可以通过批处理流协议来实现多克规模。通过对几种药物，农药，肽，手性催化剂，聚合物和有机金属配合物的修饰，证明了该策略作为后期功能化平台的优点。
• Thiazoles as inhibitors of 11B-hydroxysteroid dehydrogenase
  申请人：Gillespie Paul

  公开号：US20070167622A1

  公开（公告）日：2007-07-19

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  提供的化合物为公式(I)： 以及其中可接受的药用盐，其中取代基如说明书所述。这些化合物以及包含它们的药物组合物可用于治疗诸如2型糖尿病和代谢综合征等疾病。
• 苯并噁嗪酮衍生物及其作为抗菌剂的应用
  申请人：中国医学科学院药物研究所

  公开号：CN104211708B

  公开（公告）日：2018-08-24

  本发明公开了式(I)苯并噁嗪酮衍生物、其合成方法及其作为抗菌剂在由细菌引起的感染性疾病，特别是由分枝杆菌引起的肺结核(TB)中的应用。具体地说，本发明涉及式(I)的化合物，其药学可接受的盐以及包含本发明化合物的药物组合物，其中R1‑R4及X如说明书所述。本发明旨在制备具有抗分枝杆菌活性的新化合物，其作为潜在的新药物，可用于由细菌引起的感染性疾病，特别是由分枝杆菌引起的肺结核(TB)疾病的治疗或预防性治疗，同时可用于克服与耐药性有关的问题，以及在保持抗结核杆菌活性的基础上，改善药物代谢性质。
• [EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'ACIDE PYRIDIN-3-YL ACÉTIQUE COMME INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK (NO 5) LTD

  公开号：WO2017025864A1

  公开（公告）日：2017-02-16

  Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. In the compounds of formula (I), R1 is selected from H, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (alkoxy)alkoxyalkyl, or (R6)alkyl; R2 is phenyl substituted with 1 R7 substituent and with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; or R2 is selected from tetrahydroisoquinolinyl, ((Ar1)alkyl)tetrahydroisoquinolinyl, or ((N-alkoxycarbonyl)tetrahydroisoquinolinyl; R3 is is selected from tetrahydroisoquinolinyl or decahydroisoquinolinyl and is substituted with 0-3 substituents selected from halo, alkyl, and haloalkyl; or R3 is a [5-7.3-7.0-2] fused or bridged bicyclic amine and is substituted with 0-3 alkyl substituents; or R3 is selected from azetidinyl, pyrrolidinyl, piperidinyl, or homopiperidinyl and contains a spirocyclic moiety wherein the spirocyclic moiety, including the carbon atom to which it is attached, forms C3-7 cycloalkane, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, N-alkylpyrrolidinyl, piperidinyl, N-alkylpiperidinyl, homopiperidinyl, or N-alkylpiperidinyl, and wherein the spirocyclic moiety is substituted with 0-3 halo or alkyl substituents; R4 is selected from alkyl or haloalkyl; R5 is selected from H, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (alkoxy)alkoxyalkyl, or (R6)alkyl; R6is selected from (oxetanyl)oxy, ((oxetanyl)alkoxy)alkyl, (tetrahydropyranyloxy)alkyl, (tetrahydropyranyl)alkoxy)alkyl, or (Rg)(R9)N; R7 is selected from (Ar1)alkoxy or ((Ar1)alkyl)HNCO; R8 is selected from hydrogen, alkyl, (cycloalkyl)alkyl, alkoxyalkyl, (tetrahydropyanyl)alkyl, tetrahydropyanyl, or alkoxyphenyl; R9 is selected from hydrogen or alkyl; or (R8)(R9)N taken together is selected from azetidinyl, pyrrolidinyl, piperidinyl, (spirocyclobutyl)piperidinyl, piperazinyl, or morpholinyl; and Ar1 is phenyl substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy.

  化合物的结构式（I）包括药学上可接受的盐，包含这些化合物的药物组合物，制备这些化合物的方法以及它们在抑制HIV整合酶和治疗HIV或艾滋病感染者中的用途。在结构式（I）的化合物中，R1从H，烷基，卤代烷基，羟基烷基，烷氧基烷基，（烷氧基）烷氧基烷基或（R6）烷基中选择；R2是苯基，其上取代有1个R7取代基，以及从卤素，烷基，卤代烷基，烷氧基和卤代烷氧基中选择0-3个取代基；或者R2从四氢异喹啉基，（（Ar1）烷基）四氢异喹啉基，或（（N-烷氧羰基）四氢异喹啉基中选择；R3从四氢异喹啉基或十氢异喹啉基中选择，并取代有从卤素，烷基和卤代烷基中选择的0-3个取代基；或者R3是[5-7.3-7.0-2]融合或桥接的双环胺基，并取代有0-3个烷基取代基；或者R3从氮杂环丙烷基，吡咯啉基，哌啶基，或异哌啶基中选择，并含有一个螺环结构基团，其中螺环结构基团，包括与其相连的碳原子，形成C3-7环烷烃，四氢呋喃基，四氢吡喃基，吡咯啉基，N-烷基吡咯啉基，哌啶基，N-烷基哌啶基，异哌啶基，或N-烷基哌啶基，并且螺环结构基团取代有0-3个卤素或烷基取代基；R4从烷基或卤代烷基中选择；R5从H，烷基，卤代烷基，羟基烷基，烷氧基烷基，（烷氧基）烷氧基烷基或（R6）烷基中选择；R6从（氧杂环丙烷基）氧，（（氧杂环丙烷基）烷氧基）烷基，（四氢吡喃氧基）烷基，（四氢吡喃基）烷氧基）烷基，或（Rg）（R9）N中选择；R7从（Ar1）烷氧基或（（Ar1）烷基）HNCO中选择；R8从氢，烷基，（环烷基）烷基，烷氧基烷基，（四氢吡啶基）烷基，四氢吡啶基，或烷氧基苯基中选择；R9从氢或烷基中选择；或者（R8）（R9）N共同选择自氮杂环丙烷基，吡咯啉基，哌啶基，（螺环丁基）哌啶基，哌嗪基，或吗啉基；Ar1是苯基，其上取代有从卤素，烷基，卤代烷基，烷氧基和卤代烷氧基中选择的0-3个取代基。